ChiRhoClin, Inc.   Report issue

Contributed to NME For profit Phase 3
Founded: Burtonsville MD United States (1991)
Status: No NME R&D (1991)

Organization Overview

First Clinical Trial
2006
NCT00587132
First Marketed Drug
2002
porcine secretin
First NDA Approval
2002
porcine secretin
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

ChiRhoClin | CHIRHOCLIN | ChiRhoClin, Inc.

Active Ingredients

Marketed Drugs (2)

porcine secretin (2002 NDA)

secretin human (chirhostim) (2004)

Drugs in Phase 3 Trials (1)

secretin human (chirhostim) (7 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Abdominal Pain (Phase 3)

Adenocarcinoma (Phase 2)

Exocrine Pancreatic Insufficiency (Phase 3)

Irritable Bowel Syndrome (Phase 3)

Pancreatic Diseases (Phase 3)

Pancreatitis (Phase 2)

Pancreatitis, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 1